Keywords
Microbiome
Chronic diseases
Probiotics
Prebiotics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the relationship between intestinal dysbiosis and the development of chronic diseases, emphasizing the related pathophysiological mechanisms, as well as to enumerate the therapeutic strategies and prophylactic measures that can be used in the clinical management of dysbiosis. Bibliographic review: This review reveals significant academic and professional interest in addressing dysbiosis, from its pathophysiology to therapeutic management, highlighting the importance of an adequate nutritional diet, the use of prebiotics, probiotics, and lifestyle improvements. It is also noted that in many chronic conditions, therapeutic approaches often fail to consider or correlate the underlying disease with dysbiosis. Conclusion: For more effective clinical management of certain chronic conditions, it is essential to consider the presence of dysbiosis. Including this condition in the context of medical treatment for these individuals will allow for a more comprehensive approach, avoiding partial treatment of the disease and reducing the risk of unfavorable outcomes caused by alterations in the intestinal microbiota.
References
AKDIS CA, et al. A hipótese da barreira epitelial explica o aumento de alergias, autoimunidade e outras condições crônicas?. Nature Reviews Immunology, v. 21, n. 11, p. 739-751, 2021.
BEVILACQUA A, et al. Ultra-Processed Food and Gut Microbiota: Do Additives Affect Eubiosis? A Narrative Review. Nutrients, v. 17, n. 1, p. 2, 2024.
CALLADO L, et al. Caracterização da microbiota intestinal de pacientes brasileiros com obesidade e/ou diabetes tipo 2 e correlação com variáveis clínicas, bioquímicas e nutricionais. 2024. Tese (Doutorado) – Universidade de São Paulo.
CHEN L, et al. Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis. Immunity, Inflammation and Disease, v. 12, n. 7, p. e1356, 2024.
AKDIS CA, et al. A hipótese da barreira epitelial explica o aumento de alergias, autoimunidade e outras condições crônicas?. Nature Reviews Immunology, v. 21, n. 11, p. 739-751, 2021.
BEVILACQUA A, et al. Ultra-Processed Food and Gut Microbiota: Do Additives Affect Eubiosis? A Narrative Review. Nutrients, v. 17, n. 1, p. 2, 2024.
CALLADO L, et al. Caracterização da microbiota intestinal de pacientes brasileiros com obesidade e/ou diabetes tipo 2 e correlação com variáveis clínicas, bioquímicas e nutricionais. 2024. Tese (Doutorado) – Universidade de São Paulo.
CHEN L, et al. Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis. Immunity, Inflammation and Disease, v. 12, n. 7, p. e1356, 2024.
CHULUCK JBG, et al. A influência da microbiota intestinal na saúde humana: uma revisão de literatura. Brazilian Journal of Health Review, v. 6, n. 4, p. 16308-16322, 2023.
DA SILVA FEITOSA P, et al. Doença de Crohn e uso de probióticos como tratamento adjuvante. Brazilian Journal of Development, v. 7, n. 4, p. 42872-42889, 2021.
DA SILVA LUZ MO, et al. Epidemiologia nutricional da doença de Crohn.
DA SILVA SANTOS BP, et al. Disbiose e metabolismo. Revista Contemporânea, v. 4, n. 10, p. e6180-e6180, 2024.
DA SILVA IV, et al. Socioeconomic characteristics and the nutrition transition in Brazil: An analysis of the main national surveys from 1974 to 2019. In: Health Nutrition and Inequality in Latin America. Routledge, 2025. p. 211-228.
DE CARVALHO ACLC, et al. Utilização de simbióticos para o tratamento da disbiose e as consequentes implicações no desempenho físico. ARACÊ, v. 7, n. 4, p. 17404-17417, 2025.
DE FILIPPIS A, et al. Gastrointestinal disorders and metabolic syndrome: Dysbiosis as a key link and common bioactive dietary components useful for their treatment. International Journal of Molecular Sciences, v. 21, n. 14, p. 4929, 2020.
DE OLIVEIRA GLV, et al. Intestinal dysbiosis in inflammatory diseases. Frontiers in Immunology, v. 12, p. 727485, 2021.
DI VINCENZO F, et al. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and Emergency Medicine, v. 19, n. 2, p. 275-293, 2024.
FREJ-MĄDRZAK M, et al. The role of probiotics and prebiotics in the proper functioning of gut microbiota and the treatment of diseases caused by gut microbiota dysbiosis. Nutrition, Obesity & Metabolic Surgery, v. 7, n. 1, p. 9-15, 2020.
GUARNER F, et al. A disbiose intestinal media a associação entre exposição a antibióticos e doenças crônicas. Frontiers in Medicine, v. 11, p. 1477882, 2024.
HEMMATI M, et al. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD). Life Sciences, v. 329, p. 121947, 2023.
HUANG H, et al. Exposure to prescribed medication in early life and impacts on gut microbiota and disease development. EClinicalMedicine, v. 68, 2024.
IBRAHIM AMAR, et al. Influência da microbiota intestinal na gênese da obesidade: revisão integrativa da literatura. Saúde e Desenvolvimento Humano, v. 10, n. 1, 2022.
INTILI G, et al. From dysbiosis to neurodegenerative diseases through different communication pathways: An overview. Biology, v. 12, n. 2, p. 195, 2023.
KANDPAL M, et al. Dysbiosis of gut microbiota from the perspective of the gut–brain axis: role in the provocation of neurological disorders. Metabolites, v. 12, n. 11, p. 1064, 2022.
LIMA AER, et al. Disbiose intestinal e a relação com doenças autoimunes. Brazilian Journal of Health Review, v. 6, n. 5, p. 19852-19863, 2023.
MARQUES IVA, et al. Análise epidemiológica da Doença Inflamatória Intestinal no Brasil nos últimos 10 anos. Revista Científica do Hospital e Maternidade José Martiniano Alencar, v. 4, n. 1, p. 13-17, 2023.
MARTÍN R, et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiology Reviews, v. 47, n. 4, p. fuad039, 2023.
MERENSTEIN D, et al. Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes, 2023.
MOUSA WK, et al. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Frontiers in Immunology, v. 13, p. 906258, 2022.
MUÑOZ L, et al. A desregulação imunológica intestinal causada pela disbiose promove a ruptura da barreira e a translocação bacteriana em ratos com cirrose. Hepatology, v. 70, n. 3, p. 925-938, 2019.
NICHOLSON JS, et al. Oral dysbiosis and neurodegenerative diseases: correlations and potential causations. Microorganisms, v. 10, n. 7, p. 1326, 2022.
OLIVIER CE, et al. Considering intestinal hyperpermeability and immune-inflammatory metabolism in the treatment of food allergy. European Journal of Clinical Medicine, v. 3, n. 3, p. 13-18, 2022.
PACHECO-YANES J, et al. Microbiome-targeted interventions for the control of oral–gut dysbiosis and chronic systemic inflammation. Trends in Molecular Medicine, v. 29, n. 11, p. 912-925, 2023.
PEREIRA ALS, et al. O impacto da disbiose intestinal na saúde metabólica e imunológica. Revista Eletrônica da Estácio Recife, v. 11, p. 251-259, 2024.
PIRES LJA, et al. Um breve panorama sobre a Agenda 2030, as doenças crônicas não transmissíveis e os desafios de não deixar ninguém para trás. Cadernos de Saúde Pública, v. 40, p. e00139323, 2024.
PROFFITT C, et al. Disease, drugs and dysbiosis: understanding microbial signatures in metabolic disease and medical interventions. Microorganisms, v. 8, n. 9, p. 1381, 2020.
ROMUALDO FILHO AG, et al. Disbiose intestinal: uma abordagem nutricional. Revista Multidisciplinar do Nordeste Mineiro, v. 12, n. 2, 2024.
ROUANET A, et al. Live biotherapeutic products, a road map for safety assessment. Frontiers in Medicine, v. 7, p. 237, 2020.
GORBACH SL, et al. Studies of intestinal microflora: fecal microbial ecology in ulcerative colitis and regional enteritis. Gastroenterology, v. 54, n. 4, p. 575-587, 1968.
WEHRMEISTER C, et al. Iniquidades e doenças crônicas não transmissíveis no Brasil. Epidemiologia e Serviços de Saúde, v. 31, p. e20211065, 2022.
YAN Y, et al. Early-life gut microbiota in food allergic children and its impact on the development of allergic disease. Italian Journal of Pediatrics, v. 49, n. 1, p. 148, 2023.
YOO J, et al. Disbiose intestinal e sistema imunológico na doença cardiovascular aterosclerótica. Microorganisms, v. 10, n. 1, p. 108, 2022.
ZLATA V, et al. Impact of breastfeeding on gut microbiota formation in newborns. Professional Research in Healthcare, n. 4, p. 69-79, 2024.